{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+3&page=7",
    "query": {
      "intervention": "cohort 3",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 5394,
    "total_pages": 540,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+3&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+3&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-06T02:02:21.750Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01072266",
      "title": "A Dose-escalation Study in Subjects With Advanced Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor",
        "Advanced Cancer",
        "Metastatic Cancer"
      ],
      "interventions": [
        {
          "name": "INCB028060",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2010-01",
      "completion_date": "2013-01",
      "has_results": false,
      "last_update_posted_date": "2017-11-22",
      "last_synced_at": "2026-10-06T02:02:21.750Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Nashville, Tennessee",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01072266"
    },
    {
      "nct_id": "NCT04046224",
      "title": "Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Fabry Disease"
      ],
      "interventions": [
        {
          "name": "ST-920",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sangamo Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2019-07-23",
      "completion_date": "2025-04-10",
      "has_results": true,
      "last_update_posted_date": "2026-04-14",
      "last_synced_at": "2026-10-06T02:02:21.750Z",
      "location_count": 9,
      "location_summary": "Irvine, California • Tampa, Florida • Atlanta, Georgia + 6 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04046224"
    },
    {
      "nct_id": "NCT01110226",
      "title": "Trial Of Cisplatin And KML-001 in Platinum Responsive Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer, Small Cell Lung Cancer",
        "Platinum Responsive Malignancies"
      ],
      "interventions": [
        {
          "name": "KML-001",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2010-04-27",
      "completion_date": "2015-10-27",
      "has_results": false,
      "last_update_posted_date": "2020-03-17",
      "last_synced_at": "2026-10-06T02:02:21.750Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01110226"
    },
    {
      "nct_id": "NCT02780115",
      "title": "A Safety, Efficacy and Pharmacokinetic Study of AGN-199201 and AGN-190584 in Patients With Presbyopia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Presbyopia"
      ],
      "interventions": [
        {
          "name": "AGN-199201 ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "AGN-190584 ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "AGN-199201 Vehicle",
          "type": "DRUG"
        },
        {
          "name": "AGN-190584 Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "40 Years to 55 Years"
      },
      "enrollment_count": 151,
      "start_date": "2016-05-26",
      "completion_date": "2017-10-31",
      "has_results": true,
      "last_update_posted_date": "2020-12-22",
      "last_synced_at": "2026-10-06T02:02:21.750Z",
      "location_count": 25,
      "location_summary": "Arcadia, California • Artesia, California • Cypress, California + 19 more",
      "locations": [
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Artesia",
          "state": "California"
        },
        {
          "city": "Cypress",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02780115"
    },
    {
      "nct_id": "NCT07471308",
      "title": "P-wave Duration and Local Potential as Predictors of AF Recurrence Following Pulmonary Vein Isolation",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Atrial Fibrillation (AF)",
        "Atrial Fibrillation Patients Treated With the FARAPULSE™ PFA System",
        "Atrial Fibrillation (Paroxysmal)",
        "Pulmonary Vein Isolation"
      ],
      "interventions": [
        {
          "name": "AF Recurrence RIsk Assessment post pulmonary vein isolation",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "CathVision ApS",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2026-04-13",
      "completion_date": "2026-09-15",
      "has_results": false,
      "last_update_posted_date": "2026-08-12",
      "last_synced_at": "2026-10-06T02:02:21.750Z",
      "location_count": 1,
      "location_summary": "Paramus, New Jersey",
      "locations": [
        {
          "city": "Paramus",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07471308"
    },
    {
      "nct_id": "NCT02815917",
      "title": "Evaluation of D3 Receptor Occupancy Using FLUORTRIOPRIDE ([18F]FTP) PET/CT",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "D3 Dopamine Receptor",
        "Cocaine-dependent",
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "[18F]FTP PET/CT",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 30,
      "start_date": "2016-06",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-08-10",
      "last_synced_at": "2026-10-06T02:02:21.750Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02815917"
    },
    {
      "nct_id": "NCT04225117",
      "title": "A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced or Metastatic Malignant Solid Tumors"
      ],
      "interventions": [
        {
          "name": "enfortumab vedotin",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 329,
      "start_date": "2020-03-10",
      "completion_date": "2027-03-31",
      "has_results": true,
      "last_update_posted_date": "2026-09-23",
      "last_synced_at": "2026-10-06T02:02:21.750Z",
      "location_count": 29,
      "location_summary": "Tucson, Arizona • San Francisco, California • Aurora, Colorado + 23 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Tallahassee",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04225117"
    },
    {
      "nct_id": "NCT04021368",
      "title": "RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "High-risk Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "RVU120(SEL120)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ryvu Therapeutics SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2019-09-04",
      "completion_date": "2024-05-21",
      "has_results": false,
      "last_update_posted_date": "2026-09-18",
      "last_synced_at": "2026-10-06T02:02:21.750Z",
      "location_count": 5,
      "location_summary": "Miami, Florida • Atlanta, Georgia • St Louis, Missouri + 2 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04021368"
    },
    {
      "nct_id": "NCT02781584",
      "title": "Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Nonalcoholic Steatohepatitis (NASH)",
        "Nonalcoholic Fatty Liver Disease (NAFLD)"
      ],
      "interventions": [
        {
          "name": "SEL",
          "type": "DRUG"
        },
        {
          "name": "FIR",
          "type": "DRUG"
        },
        {
          "name": "CILO",
          "type": "DRUG"
        },
        {
          "name": "FENO",
          "type": "DRUG"
        },
        {
          "name": "VAS",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 220,
      "start_date": "2016-06-13",
      "completion_date": "2020-12-17",
      "has_results": true,
      "last_update_posted_date": "2022-03-16",
      "last_synced_at": "2026-10-06T02:02:21.750Z",
      "location_count": 12,
      "location_summary": "Chandler, Arizona • La Jolla, California • Los Angeles, California + 7 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02781584"
    },
    {
      "nct_id": "NCT00703625",
      "title": "Phase I Study of Docetaxel and Temsirolimus in Resistant Solid Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Resistant Solid Malignancies"
      ],
      "interventions": [
        {
          "name": "Temsirolimus",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2008-03-08",
      "completion_date": "2011-06-01",
      "has_results": false,
      "last_update_posted_date": "2017-03-07",
      "last_synced_at": "2026-10-06T02:02:21.750Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00703625"
    }
  ]
}